Naringenin(NAR), a naturally derived flavonoid compound, has attracted considerable attention due to its multiple pharmacological activities, including anti-inflammatory, antioxidant, anti-allergic, and antibacterial effects. This article systematically reviews the experimental and preclinical research progress of naringenin in common ocular diseases, with a focus on its potential applications in corneal neovascularization, dry eye disease, glaucoma, cataracts, and retinal disorders. Existing studies indicate that naringenin can exert protective effects on ocular tissues by regulating multiple signaling pathways, such as inhibiting inflammatory responses, alleviating oxidative stress-induced damage, and suppressing angiogenesis, thereby demonstrating promising therapeutic potential. Meanwhile, this review summarizes the research progress of ocular biopharmaceutical formulations, including naringenin eye drops, and highlights current limitations, such as its poor solubility and low bioavailability, which hinder its clinical translation. Naringenin shows unique advantages in the treatment of ocular diseases. However, future research should further clarify its molecular mechanisms, optimize drug delivery systems to enhance ocular bioavailability, and conduct well-designed clinical trials, aiming to provide new strategies and insights for the treatment of ocular diseases.